AstraZeneca Cerovive stroke data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca plans to submit its neuroprotectant Cerovive (NXY-059) for disability reduction in patients with acute ischemic stroke in the second half of 2006, the firm says May 4. AZ reported preliminary results of a pivotal trial (SAINT I) in which the free radical trapping agent showed a significant disability reduction versus placebo on the Modified Rankin Scale (p=0.038). However, "on the National Institute of Health Stroke Scale, there was no significant difference" between Cerovive and placebo. "The clinical significance of these findings need to be assessed in light of the outcome" of the ongoing SAINT II and CHANT trials. AstraZeneca is developing Cerovive with Renovis...
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.